Non-Coding RNAs as Biomarkers and Therapeutic Targets for Diabetic Kidney Disease

Front Pharmacol. 2021 Jan 26:11:583528. doi: 10.3389/fphar.2020.583528. eCollection 2020.

Abstract

Diabetic kidney disease (DKD) is the most common diabetic complication and is a leading cause of end-stage kidney disease. Increasing evidence shows that DKD is regulated not only by many classical signaling pathways but also by epigenetic mechanisms involving chromatin histone modifications, DNA methylation, and non-coding RNA (ncRNAs). In this review, we focus on our current understanding of the role and mechanisms of ncRNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) in the pathogenesis of DKD. Of them, the regulatory role of TGF-β/Smad3-dependent miRNAs and lncRNAs in DKD is highlighted. Importantly, miRNAs and lncRNAs as biomarkers and therapeutic targets for DKD are also described, and the perspective of ncRNAs as a novel therapeutic approach for combating diabetic nephropathy is also discussed.

Keywords: TGF-β; biomarker; diabetic kidney disease; fibrosis; inflammation; long non-coding RNAs; micro RNAs; therapeutic target.

Publication types

  • Review